Cardinal Capital Management Purchases 203 Shares of Masimo Co. (NASDAQ:MASI)

Cardinal Capital Management raised its position in Masimo Co. (NASDAQ:MASI) by 1.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,720 shares of the medical equipment provider’s stock after buying an additional 203 shares during the period. Cardinal Capital Management’s holdings in Masimo were worth $3,094,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. NBC Securities Inc. grew its position in Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 73 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Masimo by 5,340.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,394 shares of the medical equipment provider’s stock valued at $319,000 after buying an additional 2,350 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Masimo by 7.2% in the third quarter. State of Alaska Department of Revenue now owns 5,139 shares of the medical equipment provider’s stock valued at $685,000 after buying an additional 345 shares in the last quarter. SteelPeak Wealth LLC acquired a new position in Masimo during the 3rd quarter worth about $570,000. Finally, Roubaix Capital LLC grew its holdings in Masimo by 37.0% during the 3rd quarter. Roubaix Capital LLC now owns 34,041 shares of the medical equipment provider’s stock worth $4,539,000 after acquiring an additional 9,202 shares during the last quarter. 85.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MASI. Wells Fargo & Company upped their target price on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Piper Sandler increased their price objective on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, January 22nd. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, Raymond James boosted their price objective on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Masimo presently has an average rating of “Moderate Buy” and a consensus target price of $191.40.

Masimo Trading Up 1.0 %

NASDAQ MASI opened at $181.31 on Tuesday. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $183.14. The company has a market capitalization of $9.71 billion, a PE ratio of 125.04 and a beta of 1.02. The stock has a 50-day simple moving average of $172.65 and a 200 day simple moving average of $150.39.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.